5 December 2016 - Document will be open to public comment until 23 December 2016.

The Institute for Clinical and Economic Review has posted a draft scoping cocument that will shape an upcoming report on treatments for osteoporosis. ICER's report is expected to review the evidence on three anabolic agents: abaloparatide, romosozumab and teriparatide.

It is also anticipated that analyses in the report will provide information on the cost-effectiveness of each of these three agents, as well as potential short-term budget impact of the two emerging therapies.

The draft scoping document will be open to public comment for three weeks until 23 December 2016 at 5pm ET.

Read ICER Draft Scoping Document